In the Zone: ADA assessment and detection

The potential for a drug to induce an immune response in patients may be a critical factor in its clinical success. Anti-drug antibodies (ADAs) can impact the efficacy of the drug as well as lead to adverse safety events, so it is necessary to have in place a bioanalytical assay that can accurately determine the ADA response in patients. A critical part of ADA assay development is ensuring the assay can detect ADAs in the presence of a drug. There are several techniques that can optimize drug tolerance, such as the design of the assay and sample pretreatment. Explore the advantages and disadvantages of each technique for the development and improvement of particular ADA assays.


INFOGRAPHIC

Infographic: the facts about anti-drug antibodies – INZ CAR-TIn this infographic we give an overview of ADAs, the importance of their analysis and detection when developing a novel drug and/or therapeutic and tips and tricks in improving drug tolerance in ADA assays.

 

 

 

PODCAST

podcastADA assay development: a podcast interview with Lynn Kamen – Scientific Officer at BioAgilytix (NC, USA) Lynn Kamen explores what ADAs are and how different forms of sample pretreatment offer several advantages and disadvantages in particular ADA assay development.

 

 

RESOURCES

Bioanalysis Zone hexagon

ADA Assessment for Cell Therapies

Strategies for Overcoming Drug Interference in Immunogenicity Assessment

A cell-based FcRn-dependent recycling assay for predictive pharmacokinetic assessment of therapeutic antibodies

 

 


In association with: